1.40
-0.04(-2.78%)
Currency In USD
| Previous Close | 1.44 |
| Open | 1.47 |
| Day High | 1.5 |
| Day Low | 1.39 |
| 52-Week High | 2.59 |
| 52-Week Low | 0.49 |
| Volume | 88,044 |
| Average Volume | 247,720 |
| Market Cap | 125.59M |
| PE | -3.26 |
| EPS | -0.43 |
| Moving Average 50 Days | 0.96 |
| Moving Average 200 Days | 0.83 |
| Change | -0.04 |
If you invested $1000 in Context Therapeutics Inc. (CNTX) since IPO date, it would be worth $274.51 as of October 20, 2025 at a share price of $1.4. Whereas If you bought $1000 worth of Context Therapeutics Inc. (CNTX) shares 3 years ago, it would be worth $1,308.41 as of October 20, 2025 at a share price of $1.4.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
GlobeNewswire Inc.
Oct 06, 2025 11:30 AM GMT
PHILADELPHIA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announ
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Oct 03, 2025 8:15 PM GMT
PHILADELPHIA, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
GlobeNewswire Inc.
Jun 02, 2025 11:30 AM GMT
Dosing cohort 3 of Phase 1 trial of CTIM-76, a Claudin 6 x CD3 T cell engager Expect to share initial data in the first half of 2026 PHILADELPHIA, June 02, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX),